Sidebar Executive Summary. Mechanism of action. TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB.

Nature Reviews Drug Discovery - Glycomics: a pathway to a class of new and improved therapeutics. Skip to main content. Thank you for visiting nature.com.

We found that the effect of Class I and/or III antiarrhythmic drugs given up to around 3 months after ablation may reduce recurrence of arrhythmia at 0 to 3 months, and likely reduces recurrence at ...

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier for longer.

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the ...

Typical treatment options for MS patients involve immunomodulatory drugs, which act nonspecifically, resulting in global immunosuppression. The study discussed herein aims to demonstrate the efficacy ...

SHANGHAI and NEW YORK, June 10, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing ...

Study Shows That Existing Drug Class May Help Patients with Skin Cancer That Resists Standard Treatments. By NYU Langone Health System; Jun 10, 2025 Jun 10, 2025 Updated Jun 10, 2025; ...

President Donald Trump has been privately telling allies that Elon Musk is a “big-time drug addict,” according to a lengthy report published Saturday by The Washington Post. The newspaper ...

Avenzo’s first ADC drug candidate, AVZO-1418, is a potential best-in-class, novel EGFR/HER3 bispecific ADC that is being studied in a Phase 1/2 study for the treatment of advanced solid tumors. Avenzo ...